Where does Pangu BioPharma Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Pangu BioPharma Limited ranks #5,969 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Pangu BioPharma Limited hold?

Pangu BioPharma Limited holds 57 US utility patents granted between 2015 and 2021, spanning 8 technology areas.

What is Pangu BioPharma Limited's Innovation Score?

Pangu BioPharma Limited has an Innovation Score of 31.6 out of 100 (38th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Pangu BioPharma Limited's patent grant rate increasing or decreasing?

Pangu BioPharma Limited's recent grant velocity is -88% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Pangu BioPharma Limited's patents?

Pangu BioPharma Limited's patents average 12.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Pangu BioPharma Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Pangu BioPharma Limited

Q: What technology areas does Pangu BioPharma Limited focus on?

Pangu BioPharma Limited's top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 57 patents, ranking #180 of 4,144 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

USPTO PatentsView assignee record - 57 granted patents across 8 technology areas, recorded in grant years 2015–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Pangu ranks #5,969 of 49,997 tracked US assignees by granted-patent volume, with 57 patents across 8 technology areas.

#5,969
of 49,997 US assignees by volume: 38th percentile
by Innovation Score (31.6/100): 12.6
avg claims per patent: -88%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R5969 · Foreign Corporation #5,969 · 57 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 57 grants
UPPER-Q #5,969/49,997
PHOTO-FINISH Omnitracs
CPC-NARROW C12N · 8 areas
INNOV-THIN 31.6/100
CLAIMS-RICH 12.6 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -88% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Omnitracs, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Pangu’s 31.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 14.0 pts (44%) Velocity 0.0 pts (0%) Breadth 10.0 pts (32%) Claim depth 7.5 pts (24%)

Qualcomm Incorporated · highest

85
EBI · near

32
Feng HE Ying ZAO Group · near

32
Method Products PBC · near

32
Zhejiang Arru Pet… · near

32
Pangu BioPharma · this assignee

32
3D Lighting… · lowest

7

What this shows Pangu's Innovation Score is 31.6/100 (38th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Pangu?

Each dot is one of Pangu’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Pangu’s own 12.6 claims/patent is at or below the 16.2 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Pangu vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Pangu's grants concentrate

Pangu BioPharma Limited is a focused PatentsView assignee: 8 CPC subclasses with 100% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2015 (17 grants) versus a trough of 1 in 2021. By volume, Pangu sits between Omnitracs, LLC and RaySearch Laboratories AB.

Omnitracs

57
Ovonyx Memory Tec…

57
Phytogen Seed

57
Preformed Line Pr…

57
Poly-med

57
Production Resour…

57
Quantenna Communi…

57
Raysearch Laborat…

57
Pangu Biopharma ◀

57

What this shows Pangu holds 57 patents at rank #5,969, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Pangu

By rank, the assignees closest to #5,969 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Pangu's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Pangu, neither rank-band nor same-CPC leaders (those blocks stay above). In C12N (Microorganisms OR Enzymes), Pangu ranks #180 of 4,144 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (32 here).

EBI, LLC 32 Method Products, PBC 32 Zhejiang Arru Pet Products Co., Ltd. 32 Feng HE Ying ZAO Group Co., Ltd. 32

Similar claim depth

Nearest assignees by average claims per patent (12.6 here).

Macau University of Science and Technology 12.6 avg Atombeam Technologies Inc. 12.6 avg NEW H3C Technologies Co., Ltd. 12.6 avg Sumitomo Construction Machinery Co., Ltd. 12.6 avg

Pangu's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

32 38th percentile higher than 38% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2021

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Pangu BioPharma Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	17	29.8%
2016	11	19.3%
2017	12	21.1%
2018	4	7.0%
2019	7	12.3%
2020	5	8.8%
2021	1	1.8%

Which technologies does Pangu BioPharma Limited patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 57

C07K - Peptides 56

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 56

C12Y - Enzymes 55

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 55

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 52

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 8

Y02A - Technologies FOR Adaptation TO Climate Change 1

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Pangu BioPharma Limited's patent record in context - here's where to go next.

Pangu BioPharma Limited's lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 100% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #5,969 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Pangu BioPharma Limited against Omnitracs, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 31.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.